Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Cash & Equivalents (2016 - 2025)

Zevra Therapeutics' Cash & Equivalents history spans 11 years, with the latest figure at $62.4 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 84.72% year-over-year to $62.4 million; the TTM value through Dec 2025 reached $62.4 million, up 84.72%, while the annual FY2025 figure was $62.4 million, 84.72% up from the prior year.
  • Cash & Equivalents reached $62.4 million in Q4 2025 per ZVRA's latest filing, up from $54.4 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $132.3 million in Q2 2021 to a low of $33.8 million in Q4 2024.
  • Average Cash & Equivalents over 5 years is $66.5 million, with a median of $58.4 million recorded in 2025.
  • Peak YoY movement for Cash & Equivalents: soared 3122.28% in 2021, then tumbled 59.92% in 2023.
  • A 5-year view of Cash & Equivalents shows it stood at $112.3 million in 2021, then crashed by 41.73% to $65.5 million in 2022, then tumbled by 34.24% to $43.0 million in 2023, then fell by 21.52% to $33.8 million in 2024, then surged by 84.72% to $62.4 million in 2025.
  • Per Business Quant, the three most recent readings for ZVRA's Cash & Equivalents are $62.4 million (Q4 2025), $54.4 million (Q3 2025), and $47.7 million (Q2 2025).